
Savara (SVRA) Stock Forecast & Price Target
Savara (SVRA) Analyst Ratings
Bulls say
Savara Inc. has shown considerable improvements in Health-related Quality of Life (HrQoL) and exercise capacity across various disease-severity subgroups, demonstrating the efficacy of its main product candidate, molgramostim, in treating autoimmune pulmonary alveolar proteinosis (aPAP). The company's substantial progress in Phase 3 development, along with a de-risked Chemistry, Manufacturing, and Controls (CMC) strategy, positions it favorably for the acceptance of its Biologics License Application (BLA) and enhances the likelihood of a successful Pre-Approval Inspection. Furthermore, the company's increased probability of success to 85% boosts investor confidence, while broader adoption of diagnostic pathways enhances its launch preparedness for molgramostim.
Bears say
Savara Inc faces significant risks regarding its investment potential, primarily stemming from potential failure to secure regulatory approval for its main product candidate, molgramostim, which is currently in Phase 3 development. Additionally, the company may experience a smaller-than-anticipated commercial opportunity due to the limited market size of autoimmune pulmonary alveolar proteinosis (aPAP), competitive dynamics, and pricing pressures. The recent decision to resubmit the Biologics License Application (BLA) following a Refusal to File (RTF) letter raises concerns about the reliability of the chemistry, manufacturing, and controls (CMC) package, further complicating the company’s path to approval and market entry.
This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.
Savara (SVRA) Analyst Forecast & Price Prediction
Start investing in Savara (SVRA)
Order type
Buy in
Order amount
Est. shares
0 shares